The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (AJAX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06020014
Recruitment Status : Recruiting
First Posted : August 31, 2023
Last Update Posted : April 26, 2024
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.

Condition or disease Intervention/treatment Phase
Asthma Drug: AZD4604 Other: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
Actual Study Start Date : November 16, 2023
Estimated Primary Completion Date : September 30, 2025
Estimated Study Completion Date : September 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm 1
AZD4604
 Drug: AZD4604
AZD4604
Placebo Comparator: Arm 2
Placebo
 Other: Placebo
Placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to first CompEx Asthma event [ Time Frame: 12 weeks ]
    CompEx Asthma is a composite surrogate endpoint for exacerbations that captures: - acute worsening events based on a combination of events based on ePRO data (asthma symptoms and rescue medication use), PEF data, and severe asthma exacerbation events.


Secondary Outcome Measures :
  1. Pre-BD FEV1 [ Time Frame: 12 weeks ]
    Change from baseline in pre-bronchodilator forced expiratory volume in 1 second.

  2. CAAT [ Time Frame: 12 weeks ]
    Change from baseline in the Chronic Airways Assessment Test (CAAT). The CAAT is an 8-item patient-reported outcome measure developed to measure health status in patients with asthma and COPD.

  3. ACQ-6 [ Time Frame: 12 weeks ]
    Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6). The ACQ-6 has 6 questions (regarding asthma symptoms and rescue bronchodilator use). Answering the questions results in a score out of 6. A Score of 0 indicates complete control and 6 reflects severely uncontrolled disease.

  4. Average morning and average evening PEF [ Time Frame: 12 weeks ]
    Change from baseline in average morning and evening Peak Expiratory Flow (PEF) measurement.

  5. Daily asthma symptom score (total, daytime, and night-time) [ Time Frame: 12 weeks ]
    Change from baseline in Daily asthma symptom score. Asthma symptoms are assessed (0 to 3 scale) twice daily, once in the morning and once in the evening.

  6. Time to first CompEx acute worsening event [ Time Frame: 12 weeks ]
    Time to first CompEx Asthma acute worsening event.

  7. CompEx event rate [ Time Frame: 12 weeks ]
    The number of CompEx Asthma events recorded in the 12-week period.

  8. CompEx acute worsening event rate [ Time Frame: 12 weeks ]
    The number of CompEx Asthma acute worsening events recorded in the 12-week period.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18 to 80 years of age inclusive, at the time of signing the informed consent.
  2. Treated with medium-high dose ICS in combination with LABA at a stable dose for at least 3 months prior to Visit 1.
  3. Documented history of ≥ 1 severe asthma exacerbation within 1 year prior to Visit 1.
  4. Morning pre-BD FEV1 between ≥ 40% and ≤ 90% predicted at Visit 1 and Visit 3.
  5. Able to perform acceptable lung function testing for FEV1 according to ATS/ERS 2019 acceptability criteria.
  6. Documented evidence of asthma in the 10 years up to or including Visit 1.
  7. An ACQ-6 score ≥ 1.5 at Visit 1 and at Visit 3.

9. Body weight of ≥ 40 kg and body mass index of < 35 kg/m2. 10. Male and/or female: Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

At the end of the Run-in period (Visit 3), participants must fulfil the following additional criteria in order to be randomised into the study and enter the Treatment period:

  1. Pre-BD FEV1 between ≥ 40% and ≤ 90% predicted.
  2. A pre-BD/pre-IMP dose FEV1 at Visit 3 that has not increased or decreased by 20% or more from the pre-BD FEV1 recorded at Visit 1 and at Visit 2.
  3. An ACQ-6 score of ≥ 1.5.
  4. At least 80% compliance with usual asthma background medication during Run-in period (from Visit 2 to Visit 3) based on the daily asthma ePROs.
  5. Minimum 80% compliance with daily eCOAs (electronic Clinical Outcome Assessments) during the Run-in period and during the 14 days preceding Visit 3.
  6. For female participants, a negative urine pregnancy test prior to administration of IMP.

Exclusion Criteria:

  1. A severe asthma exacerbation within 8 weeks prior to randomisation.
  2. History of herpes zoster reactivation.
  3. Participants with a significant COVID-19 illness within 6 months of enrolment.
  4. Clinically important pulmonary disease other than asthma.

  5. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

    • affect the safety of the participant throughout the study,
    • influence the findings of the study or the interpretation, or
    • impede the participant's ability to complete the entire duration of study.
  6. Any clinically significant cardiac or cerebrovascular disease.
  7. History of venous thromboembolism.
  8. Participants who, as judged by the investigator, have evidence of active TB, or latent TB without completion of an appropriate course of treatment or appropriate ongoing prophylactic treatment.
  9. Participants with a recent history of, or who have a positive test for, infective hepatitis or unexplained jaundice, or participants who have been treated for hepatitis B, hepatitis C, or HIV.
  10. Current or prior history of alcohol or drug abuse (including marijuana), as judged by the investigator.
  11. History of malignancy other than superficial basal cell carcinoma.
  12. Treatment with systemic corticosteroid within 4 weeks (oral) or 8 weeks (intramuscular) before Visit 1.
  13. Any immunosuppressive therapy within 12 weeks prior to Visit 1.
  14. Treatment with marketed biologics within 6 months of Visit 1 or 5 half-lives, whichever is longer.
  15. Inhaled corticosteroid plus fast-acting β2 agonist as a reliever is not allowed 15 days prior to Visit 1, during Screening/Run-in and throughout the Treatment period and preferably 1 week after the last dose of IMP.
  16. Live, attenuated, or mRNA vaccines within 4 weeks of Visit 1.
  17. Immunoglobulin or blood products within 4 weeks of Visit 1.
  18. Any immunotherapy within 6 months of Visit 1, except for stable maintenance dose allergen-specific immunotherapy started at least 4 weeks prior to Visit 1 and expected to continue through to the end of the Follow-up period.
  19. Participant treated with any investigational drug within 4 months or 5 half-lives, whichever is longer, prior to Visit 1.
  20. Participants with a known hypersensitivity to AZD4604 or any of the excipients of the product.
  21. Abnormal findings identified on physical examination, ECG, or laboratory testing.
  22. For female participants only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
  23. Current smokers or participants with smoking history ≥ 10 pack-years.
  24. Participants with a known long-term exposure to occupational asbestos, silica, radon, heavy metals, and polycyclic aromatic hydrocarbons.
  25. Positive family history of lung cancer.
  26. Positive urine cotinine test or exhaled carbon monoxide test at Visit 1 and at any timepoint throughout the study.
  27. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  28. Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  29. Donation of blood (≥ 450 mL) within 3 months or donation of plasma within 14 days before Visit 1.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06020014


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Show Show 134 study locations
Sponsors and Collaborators
AstraZeneca
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT06020014    
Other Study ID Numbers: D8210C00003
First Posted: August 31, 2023    Key Record Dates
Last Update Posted: April 26, 2024
Last Verified: April 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
asthma, Janus kinase inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases